Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Receivables - Accured: 2023-2024

Historic Receivables - Accured for Roivant Sciences (ROIV) over the last 1 years, with Dec 2024 value amounting to $23.2 million.

  • Roivant Sciences' Receivables - Accured rose 22.68% to $23.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.2 million, marking a year-over-year increase of 22.68%. This contributed to the annual value of $23.2 million for FY2024, which is 22.68% up from last year.
  • According to the latest figures from Q4 2024, Roivant Sciences' Receivables - Accured is $23.2 million, which was up 67.07% from $13.9 million recorded in Q3 2024.
  • In the past 5 years, Roivant Sciences' Receivables - Accured ranged from a high of $27.4 million in Q1 2024 and a low of $4.9 million during Q1 2023.
  • For the 2-year period, Roivant Sciences' Receivables - Accured averaged around $18.5 million, with its median value being $20.8 million (2023).
  • Data for Roivant Sciences' Receivables - Accured shows a peak YoY soared of 458.99% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Roivant Sciences' Receivables - Accured stood at $18.9 million in 2023, then climbed by 22.68% to $23.2 million in 2024.
  • Its Receivables - Accured stands at $23.2 million for Q4 2024, versus $13.9 million for Q3 2024 and $22.6 million for Q2 2024.